摘要
Abstract
Objective:To explore the efficacy and safety of camrelizumab combined with bevacizumab,pemetrexed and cisplatin in elderly patients with advanced driver gene-negative non-squamous non-small cell lung cancer(NSCLC).Methods:A total of 96 elderly patients with advanced driver gene-negative non-squamous NSCLC admitted to a hospital from January 2021 to December 2022 were selected and divided into the control group(2 cases were excluded,n=46)and the observation group(2 cases were excluded,n=46)by random number table method.The control group was treated with bevacizumab injection,pemetrexed disodium for injection and cisplatin for injection.The observation group was additionally given camrelizumab for injection on the basis of the control group's treatment.Peripheral blood lymphocyte subsets(CD3+,CD4+,CD8+,CD4+/CD8+),objective response rate(ORR),disease control rate(DCR),median overall survival(OS),median progression-free survival(PFS)and adverse reactions were compared between the two groups.Results:After treatment,CD3+,CD4+and CD4+/CD8+were increased in both groups(P<0.05),with higher levels in the observation group than in the control group(P<0.05).CD8+was decreased in both groups(P<0.05),with a lower level in the observation group(P<0.05).ORR and DCR in the observation group were higher than those in the control group(P<0.05).Median OS and median PFS in the observation group were longer than those in the control group(P<0.05).There were no statistically significant differences in the incidences of bone marrow suppression,liver and kidney function impairment,gastrointestinal reactions,fatigue,anemia,hypertension,rash,immune-related pneumonia and immune-related cardiotoxicity between the two groups(P>0.05).The incidences of reactive capillary hyperplasia and hypothyroidism in the observation group were higher than those in the control group(P<0.05).Conclusion:Camrelizumab combined with bevacizumab,pemetrexed and cisplatin as first-line therapy shows good clinical efficacy in elderly patients with advanced driver gene-negative non-squamous NSCLC.It can effectively prolong survival time,delay disease progression.关键词
肺肿瘤/卡瑞利珠单抗/贝伐珠单抗/淋巴细胞亚群/疗效/安全性Key words
lung neoplasms/carilizumab/bevacizumab/lymphocyte subsets/efficacy/safety分类
医药卫生
